Now livetag icon
The official Gen AI Landscape report for 2026 is here. Don’t miss out!Get your copybanner icon
SillaJen

June 2026

SillaJen Market Share Analysis for June 2026

SillaJen is a privately-held biotechnology company focused on engineering and developing best-in-class oncolytic virus immunotherapeutics. A global leader in oncolytic immunotherapeutics Targeting, Attacking and Eradicating Cancers
Year Founded2003
Employees51 - 200
Annual Revenue$2M - $5M
sillajen.com
SillaJen
SillaJen (including company regionals)
  • sillajen.com
    sillajen.com
See more website traffic and engagement information

SillaJen Revenue up to June 2026 is 2M - 5M

revenue generated by SillaJen top domains

SillaJen top domains revenue over 3 years

Revenue for SillaJen top domains


Total visits to SillaJen's top domains

Understand SillaJen market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

Avg. visit duration in SillaJen's top domains

Analyze SillaJen engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

Avg. pageviews on SillaJen's top domains

See how SillaJen keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

Want to gain deeper traffic insights?

Filter 20.3M+ online businesses. Discover new leads when their traffic spikes, when they start or stop using technologies, or when they get positive press.



Top technologies used by SillaJen

These are the website technologies, by industry, used by SillaJen top domains

Advertising (4)

Google Adsense

Google Adsense

Conversion & Analytics (3)

Google Analytics

Google Analytics

eCommerce (3)

Social (3)

Instagram

Instagram

More Technologies

7

See all

Ready to discover high quality prospects?

Identify what technologies a website uses to craft the perfect sales pitch, and shorten the sales cycle with the Similarweb Sales Intelligence Solution.


News & Signals from SillaJen

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsSillaJen Inc. partnered with Qureator, Inc. on Jun 1st '24.To assess the synergy between BAL0891 and immune checkpoint inhibitors, SillaJen partnered in June 2024 with Qureator, a San Diego-based biotech firm specializing in 3D disease modeling.
NewsSillaJen Inc. hires Jo as CEO.CEO Jo will join SillaJen to maintain business continuity.
NewsSillaJen Inc. is developing SJ-600 series.ReiThera partners with SillaJen to develop & produce the SJ-600 series for clinical trials.

See all SillaJen signals

Focus your sales teams on the most promising opportunities. By prioritizing opportunities and engaging at the right time, you can optimize efforts and close more deals.